AbbVie Shares Drop, Analysts Eye Earnings Growth

AbbVie Inc. (ABBV) shares fell 2.4% to $182.31, underperforming a rising market with the stock now 16.62% below its 52-week high of $218.66 set in March. Over the past month, AbbVie’s stock gained just 0.63%, trailing both the Medical sector and the S&P 500. Investors are focused on the forthcoming earnings report, with analysts forecasting a 22.26% year-over-year increase in EPS and a 3.56% rise in revenue for the quarter. Full-year Zacks Consensus Estimates predict earnings growth of 21.34% and revenue growth of 6.58%. AbbVie holds a 'Hold' rating from Zacks, with no recent upward EPS revisions, highlighting analyst caution. Analyst sentiment and estimate revisions remain key for the stock’s future trajectory.